November 05, 2018

FDA Approves Novel Single-Vial Formulation of Egrifta®

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Food and Drug Administration in the United States has approved the new single-vial formulation of EGRIFTA® (tesamorelin for injection). EGRIFTA® is a growth hormone-releasing factor analog and is the only FDAapproved treatment for excess abdominal visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy.